# US 2019/0314468 A1 · Method for preventing and treating pulmonary fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314468 A1
- Document ID: US20190314468A1
- Status: Published application
- Kind: A1
- Application number: 16/470,179
- Filed: 2017-06-19
- Published: 2019-10-17
- Earliest claimed: 2016-12-15
- Assignees: Talengen International Limited
- Applicants: Talengen International Limited
- Inventors: Jinan Li
- Web page: https://patentgrep.com/patent/US20190314468A1

## CPC

- A61K 38/484: {Plasmin (3.4.21.7)}
- A61K 38/48: acting on peptide bonds (3.4)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/04: for non-specific disorders of the connective tissue
- C12Y 304/21007: Plasmin (3.4.21.7), i.e. fibrinolysin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a method for preventing and treating pulmonary fibrosis, comprising administering an effective amount of plasminogen to a subject.

## Claims

### Claim 1

A method for preventing or treating pulmonary collagen deposition or fibrosis caused by a pulmonary tissue injury in a subject, comprising administering an effective amount of plasminogen to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the injury comprises an ischemic reperfusion injury, an immune injury, a chemical-induced injury, an inflammatory injury, or a cancer-induced injury.

### Claim 3 (depends on 2)

The method of claim 2, wherein the injury comprises an autoimmune response-induced injury.

### Claim 4

A method for preventing or treating pulmonary collagen deposition or fibrosis in a subject, comprising administering an effective amount of plasminogen to the subject, wherein the subject is susceptible to pulmonary fibrosis, has a tendency of pulmonary fibrosis, or suffers from other diseases accompanied by pulmonary fibrosis.

### Claim 5

A method for treating pulmonary fibrosis in a subject with idiopathic pulmonary fibrosis, comprising administering an effective amount of plasminogen to the subject.

### Claim at position 6

-17. (canceled)

### Claim 18 (depends on 1)

The method of claim 1, comprising preventing or treating a pulmonary fibrosis-related condition in a subject, wherein the pulmonary fibrosis-related condition comprises a condition resulting from decreased pulmonary function, pulmonary dysfunction, or loss of pulmonary function due to pulmonary fibrosis.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

The method of claim 18, wherein the pulmonary fibrosis-related condition comprises pulmonary arterial hypertension, pulmonary heart disease, dyspnea, or pulmonary encephalopathy.

### Claim 21 (depends on 1)

The method of claim 1, wherein the plasminogen is administered in combination with one or more other drugs or therapeutic means.

### Claim 22 (depends on 21)

The method of claim 21, wherein the one or more other drugs comprise: a hypolipidemic drug, an anti-platelet drug, an antihypertensive drug, a vasodilator, a hypoglycemic drug, an anticoagulant drug, a thrombolytic drug, a hepatoprotective drug, an anti-fibrosis drug, an anti-arrhythmia drug, a cardiotonic drug, a diuretic drug, an anti-tumor drug, a radiotherapeutic or chemotherapeutic drug, an inflammatory regulatory drug, an immunomodulatory drug, an antiviral drug, or an antibiotic.

### Claim 23 (depends on 1)

The method of claim 1, wherein the plasminogen has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID No. 2, and still has the plasminogen activity.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the plasminogen is a protein that comprises a plasminogen active fragment and still has the plasminogen activity.

### Claim 26 (depends on 1)

The method of claim 1, wherein the plasminogen is selected from Glu-plasminogen, Lys-plasminogen, mini-plasminogen, micro-plasminogen, delta-plasminogen or their variants that retain the plasminogen activity.

### Claim 27 (depends on 1)

The method of claim 1, wherein the plasminogen is a natural or synthetic human plasminogen, or a variant or fragment thereof that still retains the plasminogen activity.

### Claim at position 17

-41. (canceled)

### Claim 42 (depends on 4)

The method of claim 4, wherein the pulmonary collagen deposition or fibrosis is caused by inhalation of toxic chemicals, radiation, or environmental pollutants, caused or accompanied by a bacterial infection, a viral infection, a chlamydial infection, a spirochetal infection, or a rickettsial infection in the lung tissue of a subject, or caused or accompanied by a pulmonary lesion in a subject.

### Claim 43 (depends on 42)

The method of claim 42, wherein the environmental pollutants comprise fog or haze.

### Claim 44 (depends on 42)

The method of claim 42, wherein the environmental pollutants comprise dust from a workshop or a workplace.

### Claim 45 (depends on 42)

The method of claim 42, wherein the environmental pollutants comprise inhalable PM2.5 particles.

### Claim 46 (depends on 42)

The method of claim 42, wherein the pulmonary lesion is pneumonia, lung cancer, pulmonary embolism, pulmonary tuberculosis, pulmonary heart disease, or pulmonary injury.

### Claim 47 (depends on 42)

The method of claim 42, wherein the pulmonary collagen deposition or fibrosis is a pulmonary collagen deposition or fibrosis accompanied by chronic obstructive pulmonary disease.

### Claim 48 (depends on 42)

The method of claim 42, wherein the bacterial infection is Mycobacterium tuberculosis infection.

### Claim 49 (depends on 1)

The method of claim 1, wherein the plasminogen is administered to the subject at a dosage of 1-100 mg/kg, 1-50 mg/kg, or 1-10 mg/kg, daily, every other day, or weekly.

### Claim 50 (depends on 49)

The method of claim 49, wherein the administration is preferably repeated at least once.

### Claim 51 (depends on 49)

The method of claim 49, wherein the plasminogen is preferably administered at least daily.
